Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study.
Diabetes care
Diabetes outcomes
Medication initiation
Newer medications
Racial disparities
Socioeconomic disparities
Journal
Lancet regional health. Americas
ISSN: 2667-193X
Titre abrégé: Lancet Reg Health Am
Pays: England
ID NLM: 9918232503006676
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
entrez:
16
3
2022
pubmed:
17
3
2022
medline:
17
3
2022
Statut:
ppublish
Résumé
Among patients with type 2 diabetes, minority racial/ethnic groups have a higher burden of cardiovascular disease, chronic kidney disease, and hypoglycaemia. These groups may especially benefit from newer diabetes medication classes, but high cost may limit access. We examined the association of race/ethnicity with the initiation of newer diabetes medications (GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors). We conducted a secondary analysis of the Look AHEAD (Action for Health in Diabetes) trial including participants with at least one study visit after April 28, 2005. Cox proportional hazards models were used to estimate the association between race/ethnicity and socioeconomic factors with time to initiation of any newer diabetes medication from April 2005 to February 2020. Models were adjusted for demographic and clinical characteristics. Among 4,892 participants, 63.6%, 15.7%, 12.6%, 5.2%, and 2.9% were White, Black, Hispanic, American Indian or Alaskan Native (AI/AN), or other race/ethnicity, respectively. During a median follow-up of 8.3 years, 2,180 (45.2%) participants were initiated on newer diabetes medications. Race/ethnicity was associated with newer diabetes medication initiation ( These findings provide evidence of racial/ethnic disparities in the initiation of newer diabetes medications, independent of socioeconomic factors, which may contribute to worse health outcomes.
Sections du résumé
Background
UNASSIGNED
Among patients with type 2 diabetes, minority racial/ethnic groups have a higher burden of cardiovascular disease, chronic kidney disease, and hypoglycaemia. These groups may especially benefit from newer diabetes medication classes, but high cost may limit access. We examined the association of race/ethnicity with the initiation of newer diabetes medications (GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors).
Methods
UNASSIGNED
We conducted a secondary analysis of the Look AHEAD (Action for Health in Diabetes) trial including participants with at least one study visit after April 28, 2005. Cox proportional hazards models were used to estimate the association between race/ethnicity and socioeconomic factors with time to initiation of any newer diabetes medication from April 2005 to February 2020. Models were adjusted for demographic and clinical characteristics.
Findings
UNASSIGNED
Among 4,892 participants, 63.6%, 15.7%, 12.6%, 5.2%, and 2.9% were White, Black, Hispanic, American Indian or Alaskan Native (AI/AN), or other race/ethnicity, respectively. During a median follow-up of 8.3 years, 2,180 (45.2%) participants were initiated on newer diabetes medications. Race/ethnicity was associated with newer diabetes medication initiation (
Interpretation
UNASSIGNED
These findings provide evidence of racial/ethnic disparities in the initiation of newer diabetes medications, independent of socioeconomic factors, which may contribute to worse health outcomes.
Identifiants
pubmed: 35291207
doi: 10.1016/j.lana.2021.100111
pmc: PMC8920048
mid: NIHMS1781199
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK057219
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK111022
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK057078
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK129474
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000043
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR003099
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK057149
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK110341
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK057136
Pays : United States
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors report no conflict of interest.
Références
Public Health Rep. 2010 May-Jun;125(3):377-88
pubmed: 20433032
J Health Care Poor Underserved. 2010 Feb;21(1):349-61
pubmed: 20173274
BMJ Open Diabetes Res Care. 2017 Sep 01;5(1):e000421
pubmed: 29225892
JAMA Netw Open. 2020 May 1;3(5):e205411
pubmed: 32442290
Diabetes Care. 2020 Jun;43(6):1209-1218
pubmed: 32238426
Lancet. 2017 Mar 25;389(10075):1229-1237
pubmed: 28159391
Circulation. 2018 May 15;137(20):2166-2178
pubmed: 29760227
Med Care. 2003 Nov;41(11):1221-32
pubmed: 14583685
Obesity (Silver Spring). 2009 Apr;17(4):713-22
pubmed: 19180071
Health Aff (Millwood). 2014 Jan;33(1):116-23
pubmed: 24395943
Int J Equity Health. 2014 Jun 02;13:43
pubmed: 24889694
Diabetes Care. 2008 Feb;31(2):261-6
pubmed: 18000177
J Urban Health. 2014 Oct;91(5):873-85
pubmed: 24532483
Control Clin Trials. 2003 Oct;24(5):610-28
pubmed: 14500058
Am J Manag Care. 2016 Jun;22(6):433-40
pubmed: 27355811
Med Care Res Rev. 2007 Oct;64(5 Suppl):101S-56S
pubmed: 17881626
Diabetes Care. 2018 Jun;41(6):1164-1171
pubmed: 29549082
Obesity (Silver Spring). 2006 May;14(5):737-52
pubmed: 16855180
Diabetes Care. 2020 Nov;43(11):2684-2690
pubmed: 32887711
Diabetes Care. 2005 Sep;28(9):2280-8
pubmed: 16123507
Diabetes Care. 2020 Jun;43(6):1227-1233
pubmed: 32234720
Diabetes Care. 2006 Sep;29(9):2130-6
pubmed: 16936167
N Engl J Med. 2013 Jul 11;369(2):145-54
pubmed: 23796131
Diabetologia. 2019 Mar;62(3):357-369
pubmed: 30607467
J Am Coll Cardiol. 2020 Feb 4;75(4):435-447
pubmed: 32000956
Metabolism. 2020 Oct;111:154343
pubmed: 32810485
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124
pubmed: 33298420